1. Treatment of Psoriasis with Interleukin-10
Kristian Reich, Andrea Gräfe, Claudia Vente, Christine Neumann 
Journal of Investigative Dermatology 
Volume 111, Issue 6, Pages (December 1998)
DOI: /j x
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

2. Figure 1
Systemic administration of IL-10 reduces the clinical activity of psoriasis. Reduction of the PASI after 3 and 6 wk in 10 patients with moderate-to-severe psoriasis injected daily for 42 d with 4 μg per kg body weight of subcutaneous rhIL-10. The patient number is followed by the gender (f, female; m, male), the age (y), and the duration of psoriasis (y). *In patient 1, treatment was stopped after 5 wk because of a newly diagnosed immunogenic hyperthyroidism.
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions

3. Figure 2
IL-10 controls epidermal hyperplasia and inflammatory infiltration in psoriasis. Example of sonographic (a, b) and histologic (c, d) improvement of the same marker lesion after treatment with IL-10 (patient 8).
Journal of Investigative Dermatology  , DOI: ( /j x)
Copyright © 1998 The Society for Investigative Dermatology, Inc Terms and Conditions